We investigated the use of infectious cDNA for the production of poliovirus type 1-type 3 recombinants. One such recombinant virus was produced, but a second construct involving the transfer of part of the capsid protein region was not infectious. Our results suggest that the approach may prove valuable but that not all cDNA constructs will give rise to viable viruses.
The three poliovirus serotypes are the causative agents of poliomyelitis, a disease which is now controlled effectively in developed countries through the use of live-attenuated or killed vaccines (16) . The polioviruses are typical members of the Picornaviridae family, possessing a single-stranded RNA genome of positive polarity, approximately 7,500 nucleotides in length (17) . The viruses have been studied extensively, and biochemical work has shed a great deal of light on the details of their replicative cycle (19) . In contrast, genetic studies have proved less productive, largely because the nature of the poliovirus genome makes it difficult to produce and analyze mutant and recombinant viruses. Although it has been shown that picornaviruses are capable of recombination in vivo and coinfection of cells with viruses carrying selectable markers, such as antigenicity and guanidine resistance, has been used to produce recombinants of footand-mouth disease virus (9) and poliovirus (2, 6, 25), these recombinants have been of limited practical use. Variation in recombination frequency means that the location of markers is inaccurate, and, because the crossover point cannot be accurately controlled, it is impossible to produce specific recombinants (5).
In 1981, Racaniello and Baltimore (18) reported that a complete cDNA copy of the Mahoney strain of poliovirus type 1 is infectious when transfected into susceptible cells. This observation had profound implications for the study of picornavirus genetics, because it opened up the possibility of circumventing the above difficulties to produce specifically designed mutant or recombinant viruses by transfecting cells with cDNA which has been modified by DNA manipulation techniques. One of the simplest applications is the use of conserved restriction enzyme sites to produce recombinants between closely related virus strains. We and others have constructed full-length cDNA copies of several strains of poliovirus types 1 and 3 and shown them to be infectious (14, 18, 21, 24 ; unpublished data). These have already been used to construct interstrain recombinants for the analysis of the molecular basis of attenuation in the poliovirus vaccine strains (10; unpublished data) and to confirm the presence of a second neutralizing antigenic site in poliovirus type 3 (12 (22, 26) . cDNAs of the three types therefore contain a number of restriction enzyme sites in common that can be used for recombination. In this communication, we describe the use of full-length cDNAs for the production of recombinants from the poliovirus type 1 and 3 Sabin vaccine strains, P1/LSc, 2ab and P3/Leon 12alb.
We first explored whether the two types of poliovirus have sufficient functional homology for specific recombinants to be made between them. The 5' nontranslated region was chosen for replacement because this region of about 740 nucleotides, although of unknown function, is highly conserved between the serotypes and, indeed, between members of different picornavirus genera (22, 23, 26) . There is, however, a region of 120 nucleotides, just before the start of the large open reading frame, which has greatly diverged between the types and which may therefore be involved in some type-specific function which renders certain recombinant viruses nonviable. In addition, our recent work has indicated that a single mutation in the 5' nontranslated region of the genome of the poliovirus type 3 vaccine strain is rapidly selected for upon passage in the gut of vaccine recipients and that virus apparently containing only this mutation possesses significantly increased neurovirulence (7) . This indicates that this region plays some role in the attenuation and reversion to neurovirulence of the type 3 vaccine strain. It is possible that such reversion would be overcome by the production of specific intertypic recombinants. When Fig. 1 . By making use of the conserved CfoI site, it is possible to produce a poliovirus type 1-type 3 cDNA chimera in the plasmid pAT 153 without perturbing the amino acid sequence of the type 1 polyprotein. The complete construction of the full-length recombinant cDNA, pOT 9, is shown in Fig. 2 . HEp-2c cells were grown to 60% confluence in 9-cm plastic dishes and transfected with 20 ,ug of pOT 9 per plate by the calcium phosphate technique using a 20% glycerol shock (15) . Cytopathic effect was observed after 5 to 7 days of incubation at 34°C, and viral RNA was prepared for sequencing after one plaque passage. The identity of the recombinant virus (OT 9) was confirmed by sequencing using two synthetic oligonucleotides to prime reverse transcription of the RNA in the presence of dideoxynucleotides. One of these was complementary to the sequence 510 to 522 (in the 5' noncoding region) of type 1 and 3 viral RNA, and one was complementary to the sequence 3006 to 3020 (in the capsid protein region) of type 1 and 3 viral RNA. The sequence obtained indicated that the virus was type 3-like in the 5' noncoding region and type 1-like in the capsid protein region and thus that the expected type 1-type 3 intertypic recombinant had been produced (data not shown).
The successful production of OT 9 led us to assess the suitability of the cDNA method for the construction of other intertypic recombinants. A major antigenic site for the neutralization of poliovirus type 3 has been located between amino acid positions 89 and 100 of capsid protein VP1 (8, 13) . One attractive possibility is to substitute this region of P3/Leon 12a1b for the corresponding region of P1/LSc, 2ab to produce a virus which is predominantly type 1 and thus presumably stable with respect to attenuation, but which has the major antigenic determinant of type 3. Between the two types, conserved Hinfl and SphI sites 228 nucleotides apart flank the cDNA corresponding to this region. In addition to the seven amino acid changes in the antigenic site, substitution of this region introduces a further seven amino acid changes. Initially, a PstI fragment of type 1 cDNA (position 2243 to 3417) was subcloned into pAT 153. The Hinfl-SphI fragment was then replaced by type 3 cDNA, as shown in Fig. 3, to give the intermediate pOT 1. The desired fulllength product, pOT 5, was obtained by ligating the PstI fragment of pOT 1 into pOLIO 1 partially digested with PstI. pOT 5 was transfected into HEp-2c cells as described above. Although several transfections were performed, each in parallel with the transfection of a control full-length cDNA which yielded virus, pOT 5 always failed to give a cytopathic effect, indicating that no virus was produced. It is possible that the noninfectious nature of pOT 5 is due to the introduction of errors into the cDNA during consiruction, particularly because the manipulations were relatively complex, and it was therefore analyzed extensively. Regtriction enzyme maps were exactly as expected, indicating that there were no gross errors and that restriction enzyme sites used for the construction were restored upon ligation. Furthermore, the whole of the chimeric 1,174-base-pair PstI fragment upon which all the manipulations were performed (Fig.   3 ) was found to have the correct nucleotide sequence. This cDNA is contained within a PstI-AvaI fragment. Partial CfoI digestion produced the PstI-Cfol fragment indicated. The 5' 1,809 nucleotides of P1/LSc, 2ab cDNA is contained within a PstI fragment, and CfoI digestion gives the CfoI-PstI fragment indicated. The two fragments were ligated, together with PstI-digested, phosphatasetreated plasmid pAT 153, and the product was used to transform competent Escherichia coli JA221 cells. The chimera pH 1 was selected fom the other possible products (head-to-head dimers or the chimera in the wrong orientation) by restriction mapping of the Tetr clones produced. pOT 9, a full-length cDNA chimera, was then made from pH 1 and pOLIO 1 (full-length P1/LSc, 2ab cDNA) by digestion at the two NruI sites, followed by ligation of the appropriate fragments. PstI fragment was excised from the full-length P1/LSc, 2ab clone pOLIO 1 and subcloned into Pst 1-digested pAT 153 to give pO 1. In addition, the fragment was digested with SplI, and the appropriate PstI-Sphl fragment was isolated and subcloned into PstI-digested pAT 153 to give a head-to-head dimer, pS 1. This was linearized by partial digestion with Sphl and then digested with BarnHI, and the indicated fragment was isolated. Complete BamHI and Hinfl digestion of pO 1 gave the fragment indicated. The 228-base-pair type 3 component was obtained by complete Sphl and partial Hinfl digestion of the cDNA insert of subclone pSGA 28 (3). The three fragments were ligated together, and the ligation mixture was used to transform E. coli JA221. The correct constructs, pOT 1, which were found to make up about 75% of the 200 clones obtained, were identified by restriction enzyme analysis. pOLIO 1 was partially digested with Pstd, and the full-length plasmid from which the 1,174-base-pair PstI fragment had been removed was isolated. The full-length chimera, pOT 5, was then produced by ligation of the PstI-digested pOLIO 1 and the purified PstI insert from pOT 1. pOT 1 is therefore full-length P1/LSc, 2ab cDNA in which nucleotides 2695 to 2923 have been replaced by the equivalent region from P3/Leon 12a,b, part of which is known to specify the major neutralizing antigenic site (8, 13) . strongly suggests that the nonviability was not due to an artifact generated during manipulation but was inherent in the final construction. Presumably, the protein-protein interactions in the poliovirus capsid are so specific that even a small number of amino acid changes, such as were transferred in pOT 5, are sufficient to prevent correct assembly or functioning of the capsid. We are now attempting to transfer larger and smaller regions of the type 3 capsid into type 1 to circumvent this problem.
In 
